Shorts

0:37
Advantages of NK Cell Therapy
a year ago
by
Katy Rezvani, MD, PhD

0:21
Understanding High-Risk Smoldering Multiple Myeloma
a year ago
by
Paula Rodriguez Otero, MD, PhD

0:28
Looking Ahead From DeLLphi-303
a year ago
by
Kelly Paulson, MD, PhD

0:31
Dr Petrylak: Unmet Needs in Prostate Cancer
a year ago
by
Daniel P. Petrylak, MD

0:29
Blood Cancer Awareness Month: Unmet Needs in Lymphoma
a year ago
by
Andrew Jallouk, MD, PhD

0:19
Dr Poh: Considerations for Tafasitamab
a year ago
by
Christina Poh, MD

0:21
Vepdegestrant for ESR1-Mutant Breast Cancer: Safety and Tolerability
a year ago
by
Erika P. Hamilton, MD

0:24
Funding Cancer Research
a year ago
by
Robert L. Ferris, MD, PhD

1:01
A New Hope: Fighting Ovarian Cancer at its Weakest
a year ago
by
Amir Jazaeri, MD

1:00
Talquetamab: The Perfect Bridge to CAR T?
a year ago
by
Binod Dhakal, MD, MS

1:10
The Race Against Time: Why CAR T-Cell Therapy Isn't a Quick Fix
a year ago
by
Binod Dhakal, MD, MS

0:18
Clinical Trial Limitations in MDS
a year ago
by
Guillermo Garcia-Manero, MD

0:17
Impactful Survival Data from the COMMANDS Trial of Luspatercept in Low-Risk MDS
a year ago
by
Guillermo Garcia-Manero, MD

0:31
Dr Wen: Treatment Considerations for Dordaviprone in Diffuse Midline Glioma
a year ago
by
Patrick Wen, MD
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Approves Neladalkib for Previously Treated Advanced ALK-Positive NSCLC
2
Galinpepimut-S Improves Overall Survival in Phase 3 REGAL Trial in AML
3
FDA Approves Giredestrant Plus Everolimus in ESR1-Mutated Breast Cancer
4
FDA Fast Tracks Elticertinib for Previously Treated EGFR Exon 20 NSCLC
5
